Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: RO7049389
Drug: Pitavastatin

First Posted Date: 2018-10-24

Last Posted Date: 2020-01-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 18

Registration Number: NCT03717064

Locations: 🇺🇸
Covance Research Unit - Daytona, Daytona Beach, Florida, United States

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Metastatic Melanoma
Solid Tumors
Non-small Cell Lung Cancer (NSCLC)
Esophageal Squamous Cell Carcinoma (ESCC)
Small Cell Lung Cancer (SCLC)

Interventions: Drug: Lomvastomig

First Posted Date: 2018-10-17

Last Posted Date: 2024-08-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 134

Registration Number: NCT03708328

Locations: 🇪🇸
Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain
🇳🇿
Auckland City Hospital; Clinical Oncology, Auckland, New Zealand
🇪🇸
START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid, Spain

and more 14 locations

A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer

Phase 1

Completed

Conditions: OVARIAN CANCER

Interventions: Drug: Cobimetinib
Drug: Niraparib
Drug: Atezolizumab

First Posted Date: 2018-10-04

Last Posted Date: 2023-08-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 77

Registration Number: NCT03695380

Locations: 🇺🇸
Medical College of Georgia; Obstetrics & Gynecolog, Augusta, Georgia, United States
🇺🇸
Stephenson Cancer Center Investigational Pharmacy, Oklahoma City, Oklahoma, United States
🇺🇸
Florida Hospital Cancer Institute; Clinical Research Department, Orlando, Florida, United States

and more 17 locations

A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Phase 3

Withdrawn

Conditions: Renal Cell Carcinoma

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2018-10-03

Last Posted Date: 2018-11-15

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT03693573

Extension Study for the Port Delivery System With Ranibizumab (Portal)

Phase 3

Recruiting

Conditions: Neovascular Age-Related Macular Degeneration

Interventions: Drug: PDS Implant with Ranibizumab 100 mg/mL

First Posted Date: 2018-09-25

Last Posted Date: 2025-05-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1000

Registration Number: NCT03683251

Locations: 🇩🇪
Knappschaftsklinikum Saar GmbH, Sulzbach, Germany
🇮🇱
Rambam Medical Center, Haifa, Israel
🇮🇱
Hadassah MC, Jerusalem, Israel

and more 131 locations

Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza

Phase 3

Completed

Conditions: Influenza

Interventions: Other: Placebo
Drug: Baloxavir Marboxil

First Posted Date: 2018-09-25

Last Posted Date: 2021-01-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 363

Registration Number: NCT03684044

Locations: 🇯🇵
Naha City Hospital, Naha, Japan
🇯🇵
Social Corporation Keigakukai Minamiosaka Hosupital, Osaka, Japan
🇯🇵
National Hospital Organaization Shibukawa Medical Center, Shibukawa, Japan

and more 167 locations

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Mosunetuzumab Intravenous (IV)
Drug: Mosunetuzumab Subcutaneous (SC)
Drug: Polatuzumab Vedotin
Drug: Tocilizumab

First Posted Date: 2018-09-19

Last Posted Date: 2025-04-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 188

Registration Number: NCT03677154

Locations: 🇮🇱
Rambam Medical Center, Haifa, Israel
🇮🇱
Carmel medical center, Haifa, Israel
🇰🇷
Severance Hospital, Yonsei University, Seoul, Korea, Republic of

and more 24 locations

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: B-cell Non-Hodgkin Lymphoma

Interventions: Drug: Mosunetuzumab
Drug: Cyclophosphamide
Drug: Polatuzumab Vedotin
Drug: Rituxumab
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine
Drug: Tocilizumab

First Posted Date: 2018-09-19

Last Posted Date: 2024-12-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 117

Registration Number: NCT03677141

Locations: 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
University of California; Moores Cancer Center, La Jolla, California, United States

and more 38 locations

A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration

Phase 3

Completed

Conditions: Neovascular Age-Related Macular Degeneration

Interventions: Drug: PDS Implant filled with 100 mg/mL Ranibizumab
Drug: Intravitreal Injections of 10 mg/mL Ranibizumab

First Posted Date: 2018-09-19

Last Posted Date: 2022-10-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 415

Registration Number: NCT03677934

Locations: 🇺🇸
Retina Specialists, Towson, Maryland, United States
🇺🇸
N CA Retina Vitreous Assoc, Mountain View, California, United States
🇺🇸
Sierra Eye Associates, Reno, Nevada, United States

and more 72 locations

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

Phase 2

Completed

Conditions: HER2-Positive Early Breast Cancer

Interventions: Drug: Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
Drug: Pertuzumab IV
Drug: Trastuzumab IV

First Posted Date: 2018-09-17

Last Posted Date: 2024-01-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 160

Registration Number: NCT03674112

Locations: 🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸
Texas Oncology - Memorial City, Houston, Texas, United States
🇨🇺
Hospital Hermanos Ameijeiras, La Habana, Cuba

and more 37 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy